Last reviewed · How we verify
DWN12088
DWN12088 is a small molecule that targets the S1P1 receptor.
DWN12088 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | DWN12088 |
|---|---|
| Also known as | DWN12088 Xmg Tablet (BID) |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | S1P1 receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By binding to the S1P1 receptor, DWN12088 modulates sphingosine-1-phosphate signaling, which plays a crucial role in various cellular processes, including immune cell trafficking and lymphocyte egress from lymphoid organs.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF (PHASE2)
- To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers (PHASE1)
- To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers (PHASE1)
- To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWN12088 CI brief — competitive landscape report
- DWN12088 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI